Cargando…
Safety and Immunogenicity of Different Formulations of Norovirus Vaccine Candidate in Healthy Adults: A Randomized, Controlled, Double-Blind Clinical Trial
BACKGROUND: We investigated safety and immunogenicity of 1–2 doses of different bivalent virus-like particle (VLP) norovirus vaccine candidate (NoV) formulations in healthy 18- to 64-year-olds. METHODS: On days 1 and 28, participants (n = 420) randomized to 14 equal groups received intramuscular con...
Autores principales: | Leroux-Roels, Geert, Cramer, Jakob P, Mendelman, Paul M, Sherwood, James, Clemens, Ralf, Aerssens, Annelies, De Coster, Ilse, Borkowski, Astrid, Baehner, Frank, Van Damme, Pierre |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5853300/ https://www.ncbi.nlm.nih.gov/pubmed/29140444 http://dx.doi.org/10.1093/infdis/jix572 |
Ejemplares similares
-
Bivalent Norovirus VLP Vaccine Candidate in Older Adults: Impact of MPL and a Second Dose in a Randomized, Controlled, Double-Blind Clinical Trial
por: Sherwood, Jim, et al.
Publicado: (2017) -
Immunogenicity and tolerability of a bivalent virus-like particle norovirus vaccine candidate in children from 6 months up to 4 years of age: A phase 2 randomized, double-blind trial
por: López, Pio, et al.
Publicado: (2023) -
2276. Immunogenicity of Takeda’s Bivalent Virus-Like Particle (VLP) Norovirus Vaccine (NoV) Candidate in Children From 6 Months up to 4 Years of Age
por: Masuda, Taisei, et al.
Publicado: (2018) -
Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials
por: De Coster, Ilse, et al.
Publicado: (2021) -
Immunogenicity and Safety of 3 Formulations of a Respiratory Syncytial Virus Candidate Vaccine in Nonpregnant Women: A Phase 2, Randomized Trial
por: Schwarz, Tino F, et al.
Publicado: (2019)